Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Penpulimab and Cisplatin in Advanced Gastric Cancer
NCT05313906Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and penpulimab in gastric cancer (GC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
disitamab vedotinpenpulimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05313906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313906.